- 肿瘤药物治疗方案及综合评价
- 李秋 张晓实主编
- 213字
- 2025-02-17 00:11:09
胃癌术后辅助化疗方案Ⅱ

方案评价

点评
术后单药S-1口服1年时间为胃癌D2术后辅助化疗方案。该ACTS-GC研究为日本研究者开展的一项大型Ⅲ期随机对照研究,旨在比较胃癌D2术后辅助S-1化疗的疗效。适用人群为Ⅱ~Ⅲ期接受D2切除术后的胃癌患者。Ⅱ期及ⅢA期患者从辅助化疗中获益更为明显。
(张 涛 于丹丹)
参考文献
[1] SASAKO M,SAKURAMOTO S,KATAI H,et al.Five-year outcomes of a randomized phase Ⅲ trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stageⅡ or Ⅲ gastric cancer.J Clin Oncol,2011,29:4387-4393.
[2] SAKURAMOTO S,SASAKO M,YAMAGUCHI T,et al.Adjuvant chemotherapy for gastric cancer with S-1,an oral fluoropyrimidine.New England Journal of Medicine,2008,358:1977-1977.